|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
61,890,000 |
Market
Cap: |
N/A |
Last
Volume: |
2,615,875 |
Avg
Vol: |
1,219,119 |
52
Week Range: |
$7.07 - $7.07 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Drug Related Products |
|
Member Indexes:
|
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Savello David R |
SVP, Development |
|
2012-03-12 |
4 |
D |
$3.93 |
$14,415 |
D/D |
(3,668) |
46,740 |
|
- |
|
Savello David R |
SVP, Development |
|
2012-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
50,408 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2012-03-12 |
4 |
D |
$3.93 |
$14,415 |
D/D |
(3,668) |
56,293 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2012-03-12 |
4 |
OE |
$0.00 |
$0 |
D/D |
10,000 |
59,961 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2012-01-30 |
4 |
D |
$4.16 |
$3,261 |
D/D |
(784) |
37,519 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2012-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,875 |
38,042 |
|
- |
|
Bosko Gianna M |
SVP, CAO, GC and secretary |
|
2012-01-30 |
4 |
D |
$4.16 |
$1,410 |
D/D |
(339) |
27,398 |
|
- |
|
Bosko Gianna M |
SVP, CAO, GC and secretary |
|
2012-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
812 |
27,633 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2012-01-30 |
4 |
D |
$4.16 |
$1,905 |
D/D |
(458) |
65,208 |
|
- |
|
Barrett Ronald W |
Chief Executive Officer |
|
2012-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,250 |
65,666 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2012-01-30 |
4 |
D |
$4.16 |
$2,608 |
D/D |
(627) |
49,961 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2012-01-30 |
4 |
OE |
$0.00 |
$0 |
D/D |
1,500 |
50,379 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2012-01-13 |
4 |
D |
$4.34 |
$13,628 |
D/D |
(3,140) |
49,088 |
|
- |
|
Harris William G |
SVP, Finance and CFO |
|
2012-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
51,705 |
|
- |
|
Bosko Gianna M |
SVP, CAO, GC and secretary |
|
2012-01-13 |
4 |
D |
$4.34 |
$12,721 |
D/D |
(2,931) |
26,925 |
|
- |
|
Bosko Gianna M |
SVP, CAO, GC and secretary |
|
2012-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,000 |
29,542 |
|
- |
|
Savello David R |
SVP, Development |
|
2012-01-13 |
4 |
D |
$4.34 |
$11,358 |
D/D |
(2,617) |
39,608 |
|
- |
|
Savello David R |
SVP, Development |
|
2012-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,250 |
41,702 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2012-01-13 |
4 |
D |
$4.34 |
$13,628 |
D/D |
(3,140) |
36,428 |
|
- |
|
Cundy Kenneth C |
SVP, Preclinical Development |
|
2012-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
39,045 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2012-01-13 |
4 |
D |
$4.34 |
$13,628 |
D/D |
(3,140) |
20,570 |
|
- |
|
Angotti Vincent |
SVP & CCO |
|
2012-01-13 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,500 |
23,187 |
|
- |
|
Rieflin William Jl |
Director |
|
2011-12-16 |
4 |
B |
$3.86 |
$38,580 |
I/I |
10,000 |
281,117 |
2.1 |
- |
|
Rieflin William Jl |
Director |
|
2011-11-21 |
4 |
B |
$4.44 |
$44,413 |
I/I |
10,000 |
271,117 |
2.1 |
- |
|
Rieflin William Jl |
Director |
|
2011-11-07 |
4 |
B |
$5.49 |
$27,452 |
I/I |
5,000 |
261,117 |
2.1 |
- |
|
663 Records found
|
|
Page 10 of 27 |
|
|